Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
PF-04457845
Cat. No.:
0225LY-0507
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
PF-04457845 serves as a highly potent FAAH inhibitor, showing nearly identical efficacy against human (IC50 = 7.2 nM) and rat (IC50 = 7.4 nM) FAAH.
Synonym:
PF04457845; PF 04457845; 1020315-31-4; Redafamdastat; 1-Piperidinecarboxamide, N-3-Pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-; N-Pyridazin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxamide
CAS No.:
1020315-31-4
Compound CID:
24771824
Formula:
C23H20F3N5O2
Formula Weight:
455.43
Specification
Targets&IC50:
FAAH (human): 7.2±0.63 nM; FAAH (rat): 7.4±0.62 nM
Relative Density:
1.389 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
PF-04457845 can be used in clinical pain research to examine the effects of irreversible FAAH inhibition on analgesic signaling.
Library Information
Target:
FAAH
Receptor:
hFAAH; rFAAH
Pathways:
Metabolism; Neuronal signaling; Autophagy
Plate Number:
AOCL-7
Plate Location:
e9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 109.79 mM
